1-3 of 3
Mark R. Albertella
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305

Krista Kinneer, Philipp Wortmann, Zachary A. Cooper, Niall J. Dickinson, Luke Masterson, Thais Cailleau, Ian Hutchinson, Balakumar Vijayakrishnan, Mary McFarlane, Kathryn Ball, Michael Davies, Arthur Lewis, Yue Huang, Anton I. Rosenbaum, Jiaqi Yuan, Jon Chesebrough, Judith Anderton, Noel Monks, Steven Novick, Jixin Wang, Nazzareno Dimasi, R. James Christie, Darrin Sabol, Frances Anne Tosto, Yann Wallez, Elisabetta Leo, Mark R. Albertella, Anna D. Staniszewska, David A. Tice, Philip W. Howard, Nadia Luheshi, Puja Sapra
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1086–1101.
https://doi.org/10.1158/1078-0432.CCR-22-2630
Published: 14 March 2023
View article titled, Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305
Open the PDF for Design and Preclinical Evaluation of a Novel B7-H4–Directed Antibody–Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305 in another window
Includes: Supplementary data
Journal Articles

Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study

Mark R. Albertella, Paul M. Loadman, Philip H. Jones, Roger M. Phillips, Roy Rampling, Neil Burnet, Chris Alcock, Alan Anthoney, Egils Vjaters, Chris R. Dunk, Peter A. Harris, Alvin Wong, Alshad S. Lalani, Chris J. Twelves
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (4): 1096–1104.
https://doi.org/10.1158/1078-0432.CCR-07-4020
Published: 15 February 2008
View article titled, Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study
Open the PDF for Hypoxia-Selective Targeting by the Bioreductive Prodrug AQ4N in Patients with Solid Tumors: Results of a Phase I Study in another window
Includes: Supplementary data
Journal Articles

Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer

Alshad S. Lalani, Susan E. Alters, Alvin Wong, Mark R. Albertella, Jeffrey L. Cleland, William David Henner
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (7): 2216–2225.
https://doi.org/10.1158/1078-0432.CCR-06-2427
Published: 02 April 2007
View article titled, Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer
Open the PDF for Selective Tumor Targeting by the Hypoxia-Activated Prodrug AQ4N Blocks Tumor Growth and Metastasis in Preclinical Models of Pancreatic Cancer in another window